Usana Health Sciences enters first amendment to credit agreement

USANA Health Sciences Inc. entered into a first amendment to its credit agreement on Sept. 30, 2026, which includes a $75 million revolver that may increase to $200 million, maturing on June 27, 2030. The amendment requires a minimum consolidated EBITDA of $100 million for the trailing four-fiscal-quarter period starting Q4 2026.